Schrödinger Discontinues Clinical Program After Two Patient Deaths
Synopsis
SGR-2921 was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Schrödinger, Inc. (SDGR) announced on Thursday that it is discontinuing the clinical development program for SGR-2921, which was being evaluated in an early-stage study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
The decision was made in light of two treatment-related deaths in the early-stage study, the company said. Schrödinger opined that developing the drug as a combination therapy would be difficult to pursue despite evidence of activity as a singular drug.
Margaret Dugan, chief medical officer at Schrödinger, said, “Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients.”
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.